The medical technology sector in 2024 witnessed a series of transformative mergers and acquisitions (M&A), highlighting the industry’s dynamic evolution and its focus on innovation, scalability, and addressing unmet medical needs. Here, we rank the top 10 M&A deals based on their financial impact and strategic significance.
1. Johnson & Johnson Acquires Shockwave Medical
- Value: $13.1 billion
- Details: This acquisition underscores J&J’s commitment to advancing intravascular lithotripsy (IVL) technology. Shockwave’s platform enhances J&J’s portfolio with innovative solutions for treating calcified coronary and peripheral artery diseases.
2. BD Purchases Edwards Lifesciences’ Critical Care Division
- Value: $4.2 billion
- Details: BD’s acquisition includes Swan-Ganz pulmonary artery catheters and other critical monitoring tools, marking a strategic expansion into advanced hemodynamic monitoring.
3. Boston Scientific Acquires Axonics
- Value: $3.7 billion
- Details: Boston Scientific’s addition of Axonics bolsters its offerings in neuromodulation technologies for urinary and bowel dysfunctions, broadening its therapeutic footprint.
4. Edwards Lifesciences Buys JenaValve and Endotronix
- Value: $1.2 billion
- Details: This dual acquisition strengthens Edwards’ leadership in structural heart innovations, with JenaValve focusing on aortic regurgitation and Endotronix delivering heart failure management solutions.
5. Boston Scientific Takes Over Silk Road Medical
- Value: $1.16 billion
- Details: With Silk Road’s transcarotid artery revascularization (TCAR) technology, Boston Scientific expands its stroke prevention portfolio for carotid artery disease.
6. Hologic Acquires Endomagnetics
- Value: $310 million
- Details: This acquisition enhances Hologic’s capabilities in breast cancer care, adding localization and lymphatic tracing solutions to its portfolio.
7. Trelleborg Sealing Solutions Acquires Barron Group
- Value: $300 million
- Details: Trelleborg strengthens its position in silicone components manufacturing, catering to the growing demand for advanced medical materials.
8. Roche Acquires LumiraDx’s Point-of-Care Assets
- Value: $295 million (initial)
- Details: Roche’s integration of LumiraDx’s POC technology complements its diagnostics division, enhancing rapid testing capabilities.
9. Alcon Acquires Belkin Vision
- Value: Up to $385 million
- Details: Alcon’s acquisition brings direct selective laser trabeculoplasty (DLST) technology for glaucoma treatment, supporting its ophthalmology portfolio.
10. Novanta Acquires Motion Solutions
- Value: $189 million
- Details: The addition of Motion Solutions strengthens Novanta’s motion subsystem capabilities, supporting applications in robotics and medical imaging.
Industry Impacts and Trends
These high-value acquisitions reflect a clear emphasis on expanding into high-growth areas such as structural heart interventions, diagnostics, and neuromodulation. Companies are leveraging M&A to integrate cutting-edge technologies, improve patient outcomes, and capture new market opportunities.
As interest rates stabilize and market conditions improve, the momentum in medtech M&A is expected to continue into 2025, promising further innovation and transformation within the sector.
Stay updated with MEDWIRE.AI for more insights into medtech’s biggest moves and trends.
